Margaret V Ragni

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. pmc Phase II prospective open-label trial of recombinant interleukin-11 in desmopressin-unresponsive von Willebrand disease and mild or moderate haemophilia A
    Margaret V Ragni
    Department of Medicine, Division of Hematology Oncology and Vascular Medicine Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    Thromb Haemost 109:248-54. 2013
  2. doi request reprint Challenges of rare disease research: limited patients and competing priorities
    M V Ragni
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213 4306, USA
    Haemophilia 18:e192-4. 2012
  3. pmc Impact of HIV on liver fibrosis in men with hepatitis C infection and haemophilia
    M V Ragni
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh, Pittsburgh, PA 15213 4306, USA
    Haemophilia 17:103-11. 2011
  4. ncbi request reprint Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease
    Margaret V Ragni
    Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213 4306, USA
    Liver Transpl 11:1425-30. 2005
  5. ncbi request reprint Tissue plasminogen activator to prevent central venous access device infections: a systematic review of central venous access catheter thrombosis, infection and thromboprophylaxis
    M V Ragni
    Division Hematology Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213 4306, USA
    Haemophilia 14:30-8. 2008
  6. pmc Atherosclerotic heart disease: prevalence and risk factors in hospitalized men with haemophilia A
    M V Ragni
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213 4306, USA
    Haemophilia 17:867-71. 2011
  7. doi request reprint Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centres
    M V Ragni
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213 4306, USA
    Haemophilia 18:63-8. 2012
  8. doi request reprint Phase II prospective open-label trial of recombinant interleukin-11 in women with mild von Willebrand disease and refractory menorrhagia
    Margaret V Ragni
    Division Hematology Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    Thromb Haemost 106:641-5. 2011
  9. ncbi request reprint Pulmonary embolism and spiral computerized tomographic scans
    Margaret V Ragni
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213 4306, USA
    Curr Opin Pulm Med 15:430-8. 2009
  10. ncbi request reprint On the cutting edge: von Willebrand factor propeptide and thrombosis
    M V Ragni
    Department of Medicine, Division of Hematology and Oncology, University of Pittsburgh, and Hemophilia Center of Western PA, Pittsburgh, PA 15213, USA
    J Thromb Haemost 4:2553-5. 2006

Detail Information

Publications51

  1. pmc Phase II prospective open-label trial of recombinant interleukin-11 in desmopressin-unresponsive von Willebrand disease and mild or moderate haemophilia A
    Margaret V Ragni
    Department of Medicine, Division of Hematology Oncology and Vascular Medicine Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    Thromb Haemost 109:248-54. 2013
    ..In summary, rhIL-11 increases VWF levels in two of four DDAVP-unresponsive or allergic VWD and F.VIII levels in four of five mild or moderate haemophilia A subjects, suggesting its potential use in treatment of these disorders...
  2. doi request reprint Challenges of rare disease research: limited patients and competing priorities
    M V Ragni
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213 4306, USA
    Haemophilia 18:e192-4. 2012
    ..Thus, the milestones we achieve in this ongoing process will hopefully not only enable clinical trials research in a rare disease, but also in many medical genetic disease of the future...
  3. pmc Impact of HIV on liver fibrosis in men with hepatitis C infection and haemophilia
    M V Ragni
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh, Pittsburgh, PA 15213 4306, USA
    Haemophilia 17:103-11. 2011
    ..Nearly one-fourth of haemophilic men have Metavir ≥ 3 fibrosis. The odds for developing fibrosis are increased in those with elevated alpha-fetoprotein, increasing age and past HCV treatment...
  4. ncbi request reprint Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease
    Margaret V Ragni
    Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213 4306, USA
    Liver Transpl 11:1425-30. 2005
    ..05. In conclusion, pretransplant survival appears shorter in HIV-positive OLTX candidates and is unrelated to severity of liver or HIV disease. Further study is warranted to determine risk factors for poorer pretransplant outcomes...
  5. ncbi request reprint Tissue plasminogen activator to prevent central venous access device infections: a systematic review of central venous access catheter thrombosis, infection and thromboprophylaxis
    M V Ragni
    Division Hematology Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213 4306, USA
    Haemophilia 14:30-8. 2008
    ..Clinical trials to evaluate t-PA in CVAD infection prevention are justified...
  6. pmc Atherosclerotic heart disease: prevalence and risk factors in hospitalized men with haemophilia A
    M V Ragni
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213 4306, USA
    Haemophilia 17:867-71. 2011
    ..These findings suggest that cardiovascular prevention measures should be promoted in haemophilia...
  7. doi request reprint Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centres
    M V Ragni
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213 4306, USA
    Haemophilia 18:63-8. 2012
    ....
  8. doi request reprint Phase II prospective open-label trial of recombinant interleukin-11 in women with mild von Willebrand disease and refractory menorrhagia
    Margaret V Ragni
    Division Hematology Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    Thromb Haemost 106:641-5. 2011
    ..0-13.5). rhIL-11 was well tolerated with grade 1 or less fluid retention, flushing, conjunctival erythema, and local bruising. In summary, rhIL-11 reduces menorrhagia safely and warrants further study...
  9. ncbi request reprint Pulmonary embolism and spiral computerized tomographic scans
    Margaret V Ragni
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213 4306, USA
    Curr Opin Pulm Med 15:430-8. 2009
    ..The purpose of this review is to summarize the state-of-the-art of radiographic pulmonary embolism detection and consider future directions to reduce this significant public health problem...
  10. ncbi request reprint On the cutting edge: von Willebrand factor propeptide and thrombosis
    M V Ragni
    Department of Medicine, Division of Hematology and Oncology, University of Pittsburgh, and Hemophilia Center of Western PA, Pittsburgh, PA 15213, USA
    J Thromb Haemost 4:2553-5. 2006
  11. pmc Highly active antiretroviral therapy improves ESLD-free survival in HIV-HCV co-infection
    M V Ragni
    Department of Medicine, Division Hematology Oncology, University of Pittsburgh Medicine Center, Pittsburgh, PA 15213 4306, USA
    Haemophilia 15:552-8. 2009
    ..HIV+ HAART Rx and HIV- did not differ in HCV duration, age at ESLD, age at death or present, overall or AIDS mortality, all P > 0.05. These data suggest that HAART improves ESLD-free survival, approaching that in HIV- men...
  12. pmc A phase II prospective open-label escalating dose trial of recombinant interleukin-11 in mild von Willebrand disease
    M V Ragni
    Department of Medicine Hematology Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    Haemophilia 14:968-77. 2008
    ..Recombinant IL-11 increases VWF levels in humans with mild VWD, justifying future clinical trials to determine its potential in preventing or reducing bleeding in this patient population...
  13. pmc No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation
    Veronica H Flood
    Department of Pediatrics, Division of Hematology Oncology, Medical College of Wisconsin, Milwaukee, WI, USA
    Blood 121:3742-4. 2013
    ..These results suggest that the presence of the D1472H sequence variation is not associated with a significant increase in bleeding symptoms, even in type 1 VWD subjects...
  14. ncbi request reprint Survival of human immunodeficiency virus-infected liver transplant recipients
    Margaret V Ragni
    Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15213 4306, USA
    J Infect Dis 188:1412-20. 2003
    ..Further prospective studies are warranted...
  15. doi request reprint Anticoagulation in ambulatory cancer patients with no indication for prophylactic or therapeutic anticoagulation: a cost-effectiveness analysis from a U.S. perspective
    Allyson M Pishko
    Department of Medicine, Division Hematology Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania 15213 4306, USA
    Thromb Haemost 108:303-10. 2012
    ..In conclusion, prophylactic LMWH given to decrease cancer-related mortality, with no conventional indication, appears economically reasonable if its suggested mortality benefit is confirmed in future trials...
  16. pmc Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis Trial
    Margaret V Ragni
    University of Pittsburgh Medical Center, Department of Medicine, Division Hematology Oncology, and Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA
    Expert Rev Hematol 4:495-507. 2011
    ....
  17. ncbi request reprint Safety of the new generation recombinant factor concentrates
    Kimberly W Schlesinger
    Hemophilia Center of Western Pennsylvania, 3636 Boulevard of the Allies, Pittsburgh, PA 15213 4306, USA
    Expert Opin Drug Saf 1:213-23. 2002
    ..Despite this, recombinant factors remain the most attractive treatment approach for haemophilia. Future improvement awaits the development of safe and effective gene transfer technology...
  18. pmc Pulmonary embolism incidence is increasing with use of spiral computed tomography
    Nicholas A DeMonaco
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
    Am J Med 121:611-7. 2008
    ..Pulmonary embolism causes significant morbidity in hospitalized patients, yet few studies have explored the impact of spiral computed tomography (CT) scanning on diagnosis and clinical outcome...
  19. ncbi request reprint Genetics of bleeding disorders in women
    Enrico M Novelli
    Department of Medicine, Division of Hematology and Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Semin Thromb Hemost 34:509-19. 2008
    ..The purpose of this article is to review the genetics of inherited bleeding disorders in women, focusing on bleeding manifestations, diagnostic methodologies, and management...
  20. ncbi request reprint Hemophilia gene transfer: comparison with conventional protein replacement therapy
    Margaret V Ragni
    Division Hematology, Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213 4606, USA
    Semin Thromb Hemost 30:239-47. 2004
    ..This article reviews and compares the risks and benefits of standard protein-based therapy with those of gene transfer, and considers how gene transfer might fit into state-of-the-art management of hemophilia...
  21. ncbi request reprint AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
    Catherine S Manno
    Department of Pediatrics, University of Pennsylvania and The Children s Hospital of Philadelphia, PA, 19104, USA
    Blood 101:2963-72. 2003
    ....
  22. pmc Risk factors for inhibitor formation in haemophilia: a prevalent case-control study
    M V Ragni
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213 4306, USA
    Haemophilia 15:1074-82. 2009
    ..The ideal time to initiate prophylaxis to reduce CNS bleeding and inhibitor formation will require prospective studies...
  23. doi request reprint Viral pathogens
    M V Ragni
    Department of Medicine, Division Hematology Oncology, University of Pittsburgh Medical Center and Hemophilia Center of Western Pennsylvania, Pittsburgh, PA 15213 4306, USA
    Haemophilia 16:40-6. 2010
    ..The purpose of this chapter is to provide an update on three clinically significant transfusion-transmitted viral pathogens...
  24. ncbi request reprint New-generation recombinant factor concentrates: bridge to gene therapy
    M V Ragni
    University of Pittsburgh Medical Center and Hemophilia Center of Western Pennsylvania, Pittsburgh, PA 15213 4306, USA
    Haemophilia 7:28-35. 2001
    ..It is likely that improvement in safety and reduction in immunogenicity will require modification not only of antigenic structure but also of the immune response to coagulation proteins...
  25. ncbi request reprint Use of recombinant factor IX in subjects with haemophilia B undergoing surgery
    M V Ragni
    University of Pittsburgh School of Medicine, General Clinical Research Center, Hemophilia Center of Western Pennsylvania, Pittsburgh 15213, USA
    Haemophilia 8:91-7. 2002
    ..Thus, rFIX was found to be safe and effective in achieving haemostasis in subjects with FIX deficiency undergoing surgery...
  26. ncbi request reprint Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection
    M V Ragni
    Department of Medicine, University of Pittsburgh Medical Center and Hemophilia Center of Western Pennsylvania, Pittsburgh, PA 15213 4306, USA
    J Infect Dis 183:1112-5. 2001
    ..03-1.14; P=.069) and increased with each decade of HCV infection (RR, 2.26; 95% CI, 1.42-3.59; P=.0006) and HIV infection (RR, 2.18; 95% CI, 1.36-3.49; P=.0013). These findings suggest that HIV accelerates HCV disease progression...
  27. ncbi request reprint Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapy
    M V Ragni
    Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    J Infect Dis 180:2027-9. 1999
    ..With discontinuation of HAART, HCV RNA decreased as HIV RNA rebounded. Further study is required to clarify the histopathologic significance of this finding...
  28. doi request reprint Coagulation factor VIIa (recombinant) in nonhemophilic patients requiring neurosurgery
    Colleen M Culley
    Drug Use and Disease State Management DUDSM Program, Department of Pharmacy and Therapeutics, University of Pittsburgh Medical Center UPMC, Pittsburgh, PA 15213, USA
    Am J Health Syst Pharm 66:1554-9. 2009
    ..The clinical outcomes, safety, and use of resources associated with the administration of factor VIIa (recombinant) to nonhemophilic patients requiring neurosurgery were evaluated...
  29. pmc Plasma thrombospondin-1 is increased during acute sickle cell vaso-occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates
    Enrico M Novelli
    Division of Hematology Oncology, University of Pittsburgh Medical Center UPMC, Vascular Medicine Institute VMI, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Am J Hematol 87:326-30. 2012
    ..Our results suggest that TSP1 levels are associated with more VOE, hydroxyurea use and lower rates of hemolysis. High TSP1 concentrations may indicate higher risk of the viscosity/vaso-occlusion phenotype of SCD...
  30. doi request reprint Cost-utility analysis of von Willebrand disease screening in adolescents with menorrhagia
    Robert Francis Sidonio
    Division of Pediatric Hematology Oncology, Children s Hospital of Pittsburgh University of Pittsburgh Medical Center, Pittsburgh, PA 15201, USA
    J Pediatr 157:456-60, 460.e1. 2010
    ..To construct a decision analysis model to evaluate the cost utility of von Willebrand disease (VWD) testing in adolescents with menorrhagia...
  31. pmc Porcine and canine von Willebrand factor and von Willebrand disease: hemostasis, thrombosis, and atherosclerosis studies
    Timothy C Nichols
    Department of Medicine, Francis Owen Blood Research Laboratory, University of North Carolina, Chapel Hill, NC 27516, USA
    Thrombosis 2010:461238. 2010
    ..The current status of porcine and canine VWD are also reviewed as well as their potential role in future studies of VWF-related disorders of hemostasis and thrombosis...
  32. ncbi request reprint Association of venous thromboembolism with human immunodeficiency virus and mortality in veterans
    Shawn L Fultz
    Center for Health Equity Research and Promotion, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA
    Am J Med 116:420-3. 2004
  33. ncbi request reprint Cumulative risk for AIDS and other HIV outcomes in a cohort of hemophiliacs in western Pennsylvania
    M V Ragni
    Department of Medicine, University of Pittsburgh School of Medicine, PA
    J Acquir Immune Defic Syndr 3:708-13. 1990
    ..01). In conclusion, (a) nearly half of this cohort is estimated to develop AIDS by 7 1/2 years' duration of infection, and (b) older age is associated with significantly shorter time to AIDS and shorter survival once AIDS occurs...
  34. ncbi request reprint Progression of HIV in haemophilia
    M V Ragni
    University of Pittsburgh School of Medicine, PA 15213 4306, USA
    Haemophilia 4:601-9. 1998
    ....
  35. ncbi request reprint Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C
    M E De Vera
    Thomas E Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Am J Transplant 6:2983-93. 2006
    ..Hepatitis C is a major cause of graft loss and patient mortality in coinfected patients undergoing LTx...
  36. ncbi request reprint Anticardiolipin antibody associated arterial thrombosis following fibula fracture
    Thomas H Vikoren
    Department of Orthopaedic Surgery, University of Pittsburgh, PA, USA
    Foot Ankle Int 24:270-3. 2003
    ..Additional risk factors such as oral contraceptive use, should be sought during the initial history...
  37. ncbi request reprint Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis
    Kenneth J Smith
    Medicine Hematology Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213 4306, USA
    Thromb Haemost 100:447-52. 2008
    ..In conclusion, screening, counselling and prophylactic AC during high-risk periods in female relatives of FVL carriers is an economically favourable strategy...
  38. pmc Factor VIII-pulsed dendritic cells reduce anti-factor VIII antibody formation in the hemophilia A mouse model
    Margaret V Ragni
    Medicine Hematology Oncology, University of Pittsburgh Medicine Center, Pittsburgh, PA 15213 4306, USA
    Exp Hematol 37:744-54. 2009
    ..VIII-pulsed DCre, propagated from bone marrow in the presence of granulocyte-macrophage colony-stimulating factor and transforming growth factor-beta, in achieving F.VIII tolerance...
  39. ncbi request reprint Safe passage: a plea for safety in hemophilia gene therapy
    Margaret V Ragni
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, and Hemophilia Center of Western PA, Pittsburgh, Pennsylvania 15213 4306, USA
    Mol Ther 6:436-40. 2002
  40. ncbi request reprint Lack of desmopressin (DDAVP) response in men with hemophilia A following liver transplantation
    P A Lamont
    Department of Medicine, University of Pittsburgh School of Medicine, Division of Hematology and Oncology, Pittsburgh, PA 15213 4306, USA
    J Thromb Haemost 3:2259-63. 2005
    ..By contrast, both VWF and FVIII increased in a non-hemophilic transplant recipient after DDAVP. These findings support a model in which intracellular co-localization of FVIII and VWF is necessary for in vivo FVIII secretion after DDAVP...
  41. ncbi request reprint Bleeding manifestations in males with von Willebrand disease
    O Ziv
    Department of Medicine, University of Pittsburgh School of Medicine, The Hemophilia Center of Western Pennsylvania and The Institute of Transfusion Medicine, Pittsburgh, PA 15213 7281, USA
    Haemophilia 10:162-8. 2004
    ..The failure to avoid postoperative bleeding and related complications in patients with vWD by taking a personal and family bleeding history constitutes a major public health problem...
  42. doi request reprint Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: a U.S. perspective
    Craig D Seaman
    Department of Medicine, Division Hematology Oncology, University of Pittsburgh, USA
    Thromb Res 132:647-51. 2013
    ..Rivaroxaban is an oral direct factor Xa inhibitor that is noninferior to warfarin in the prevention of recurrent venous thromboembolism (VTE). Whether rivaroxaban is cost-effective in the prevention of recurrent VTE, however, is not known...
  43. doi request reprint Anticoagulation duration in heterozygous factor V Leiden: a decision analysis
    Anna K Donovan
    Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    Thromb Res 132:724-8. 2013
    ..Among individuals heterozygous for the factor V Leiden mutation, while venous thromboembolism recurrence risk is greater, the risk for bleeding is recognized to be lower, suggesting longer duration anticoagulation could be considered...
  44. pmc Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor
    Veronica H Flood
    Department of Pediatrics, Division of Hematology Oncology, Medical College of Wisconsin, Milwaukee, WI 53201, USA
    Blood 116:280-6. 2010
    ..Because the VWF:RCo assay depends on ristocetin binding to VWF, mutations (and polymorphisms) in VWF may affect the measurement of "VWF activity" by this assay and may not reflect a functional defect or true hemorrhagic risk...
  45. ncbi request reprint Disappearance of inhibitor to factor VIII in HIV-infected hemophiliacs with progression to AIDS or severe ARC
    M V Ragni
    Department of Medicine, University of Pittsburgh School of Medicine, Pennsylvania
    Transfusion 29:447-9. 1989
    ..The mechanism by which the anti-FVIII inhibitor disappears is not known, but it is likely to be related to a quantitative decline in T4 cell number...
  46. ncbi request reprint Acquired anti-FVIII inhibitors in children
    R J Moraca
    The Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Medical Center, PA, USA
    Haemophilia 8:28-32. 2002
    ..In conclusion, acquired anti-FVIII inhibitors in children may cause severe bleeding, and remit in the majority after FVIII and/or immunosuppressive therapy...
  47. ncbi request reprint von Willebrand disease and bleeding in women
    M V Ragni
    Department of Medicine, University of Pittsburgh School of Medicine, USA, Pittsburgh, Pennsylvania, USA
    Haemophilia 5:313-7. 1999
    ..Obtaining a personal and family bleeding history promotes early diagnosis, potentially prevents postoperative bleeding, and improves the health of women with vWD...
  48. ncbi request reprint Clinical manifestations and management of labor and delivery in women with factor IX deficiency
    M Y Yang
    Division of Hematology and Oncology, Department of Medicine, University of Pittsburgh School of Medicine, and The Hemophilia Center of Western Pennsylvania, Pittsburgh, PA 15213, USA
    Haemophilia 10:483-90. 2004
    ..Postpartum bleeding is common in women with haemophilia B or carriers of haemophilia B, and treatment with factor replacement for at least 4 days of postpartum may prevent bleeding following delivery in such women...
  49. ncbi request reprint Liver transplantation in HIV-seropositive individuals
    Margaret V Ragni
    Ann Intern Med 144:223; author reply 223-4. 2006
  50. ncbi request reprint Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion
    Jerry S Powell
    Division of Hematology and Oncology, Suite 3016, UC Davis Cancer Center, University of California at Davis, 4501 X St, Sacramento, CA 95817
    Blood 102:2038-45. 2003
    ....
  51. ncbi request reprint CD8(+) T-cell responses to adeno-associated virus capsid in humans
    Federico Mingozzi
    The Children s Hospital of Philadelphia, 3615 Civic Center Boulevard, Philadelphia, Pennsylvania 19104, USA
    Nat Med 13:419-22. 2007
    ..In addition, we show that AAV-2 induced human T cells proliferate upon exposure to alternate AAV serotypes, indicating that other serotypes are unlikely to evade capsid-specific immune responses...